etoposide has been researched along with icrf 198 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, WP; Creighton, AM; Fattman, CL; Hasinoff, BB; Kuschak, TI; Thampatty, P; Yalowich, JC | 1 |
| Hasinoff, BB; Hofland, KF; Jensen, PB; Langer, SW; Schroeder, PE; Sehested, M | 1 |
2 other study(ies) available for etoposide and icrf 198
| Article | Year |
|---|---|
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Topics: Aclarubicin; Animals; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance; Ethylenediamines; Etoposide; Glycine; Mutation; Razoxane; Thiobarbiturates; Topoisomerase II Inhibitors; Verapamil | 1997 |
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Ethylenediamines; Etoposide; Female; Glycine; Half-Life; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Razoxane | 2003 |